Literature DB >> 20118449

Acute antipsychotic-induced akathisia revisited.

Michael Poyurovsky.   

Abstract

Akathisia remains one of the most prevalent and distressful antipsychotic-induced adverse events. Effective and well-tolerated treatment is a major unmet need in akathisia that merits a search for new remedies. Accumulating evidence indicates that agents with marked serotonin-2A receptor antagonism may represent a new class of potential anti-akathisia treatment.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20118449     DOI： 10.1192/bjp.bp.109.070540

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN： 0007-1250            Impact factor:   9.319


  19 in total

1.  Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

Authors:  Stanley N Caroff; Irene Hurford; Janice Lybrand; E Cabrina Campbell
Journal:  Neurol Clin       Date:  2011-02       Impact factor: 3.806

Review 2.  The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs.

Authors:  Mario Rossi; Irene Fasciani; Francesco Marampon; Roberto Maggio; Marco Scarselli
Journal:  Mol Pharmacol       Date:  2017-03-06       Impact factor: 4.436

3.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

4.  Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.

Authors:  Maria Juncal-Ruiz; Mariluz Ramirez-Bonilla; Jorge Gomez-Arnau; Victor Ortiz-Garcia de la Foz; Paula Suarez-Pinilla; Obdulia Martinez-Garcia; Karl David Neergaard; Rafael Tabares-Seisdedos; Benedicto Crespo-Facorro
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

5.  Structured relaxation in the treatment of akathisia: case series.

Authors:  Lars K Hansen; Thomas L'allemand; Francine Thiry; David S Baldwin
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-25       Impact factor: 2.570

6.  Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study.

Authors:  Bunta Yoshimura; Kojiro Sato; Shinji Sakamoto; Masaru Tsukahara; Yusaku Yoshimura; Ryuhei So
Journal:  Psychopharmacology (Berl)       Date:  2018-11-15       Impact factor: 4.530

7.  The Assessment and Treatment of Antipsychotic-Induced Akathisia.

Authors:  Tamara Pringsheim; David Gardner; Donald Addington; Davide Martino; Francesca Morgante; Lucia Ricciardi; Norman Poole; Gary Remington; Mark Edwards; Alan Carson; Thomas R E Barnes
Journal:  Can J Psychiatry       Date:  2018-04-23       Impact factor: 4.356

8.  Amisulpride-induced acute akathisia in OCD: an example of dysfunctional dopamine-serotonin interactions?

Authors:  Karen D Ersche; Paul Cumming; Kevin J Craig; Ulrich Müller; Naomi A Fineberg; Edward T Bullmore; Trevor W Robbins
Journal:  J Psychopharmacol       Date:  2011-07-11       Impact factor: 4.153

Review 9.  Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges.

Authors:  Haitham Salem; Caesa Nagpal; Teresa Pigott; Antonio Lucio Teixeira
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 10.  Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice.

Authors:  Robert A Hauser; Jonathan M Meyer; Stewart A Factor; Cynthia L Comella; Caroline M Tanner; Rose Mary Xavier; Stanley N Caroff; Leslie Lundt
Journal:  CNS Spectr       Date:  2020-11-20       Impact factor: 4.604
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.